Novartis Pays US$100 M Upfront for Legend Biotech’s CAR-T Cell Therapies
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 11 (Table of Contents)
Published: 29 Nov-2023
DOI: 10.3833/pdr.v2023.i11.2838 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novartis has signed a global licensing agreement with Legend Biotech to advance the latter’s chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including LB1102 for the treatment of extensive stage small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS